9.6299
price down icon1.18%   -0.1101
 
loading
前日終値:
$9.74
開ける:
$9.63
24時間の取引高:
64,827
Relative Volume:
0.07
時価総額:
$2.52B
収益:
$7.94B
当期純損益:
$225.54M
株価収益率:
29.19
EPS:
0.3299
ネットキャッシュフロー:
$709.16M
1週間 パフォーマンス:
-0.05%
1か月 パフォーマンス:
-5.27%
6か月 パフォーマンス:
+23.56%
1年 パフォーマンス:
+7.54%
1日の値動き範囲:
Value
$9.615
$9.66
1週間の範囲:
Value
$9.615
$10.06
52週間の値動き範囲:
Value
$6.19
$11.14

Grifols Sa Adr Stock (GRFS) Company Profile

Name
名前
Grifols Sa Adr
Name
セクター
Healthcare (1156)
Name
電話
-
Name
住所
-
Name
職員
23,800
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
GRFS's Discussions on Twitter

GRFS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
GRFS
Grifols Sa Adr
9.625 6.63B 7.94B 225.54M 709.16M 0.3299
Drug Manufacturers - General icon
LLY
Lilly Eli Co
758.79 674.13B 53.26B 13.80B -50.20M 15.30
Drug Manufacturers - General icon
JNJ
Johnson Johnson
175.54 424.33B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
224.64 393.01B 58.33B 3.73B 18.24B 2.10
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
123.71 237.97B 53.40B 13.68B 16.89B 6.9231
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
60.70 272.83B 45.44B 16.18B 9.21B 3.634

Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-12 再開されました Morgan Stanley Overweight
2024-03-12 ダウングレード Deutsche Bank Hold → Sell
2023-04-12 アップグレード Morgan Stanley Equal-Weight → Overweight
2023-03-03 ダウングレード Morgan Stanley Overweight → Equal-Weight
2023-02-16 アップグレード Barclays Underweight → Equal Weight
2023-01-18 アップグレード Jefferies Hold → Buy
2022-04-08 開始されました Morgan Stanley Equal-Weight
2021-11-05 ダウングレード Deutsche Bank Buy → Hold
2021-10-19 ダウングレード Barclays Overweight → Underweight
2021-10-06 アップグレード Citigroup Neutral → Buy
2021-06-14 アップグレード Deutsche Bank Hold → Buy
2021-04-20 開始されました Deutsche Bank Hold
2021-03-23 アップグレード Credit Suisse Neutral → Outperform
2021-03-11 アップグレード HSBC Securities Hold → Buy
2020-10-01 アップグレード Citigroup Sell → Neutral
2020-06-09 ダウングレード Citigroup Neutral → Sell
2020-06-09 アップグレード HSBC Securities Reduce → Hold
2020-03-25 ダウングレード Citigroup Buy → Neutral
2019-06-27 アップグレード JP Morgan Neutral → Overweight
2019-02-08 ダウングレード Berenberg Buy → Hold
2018-10-11 アップグレード Berenberg Hold → Buy
2018-06-01 開始されました Barclays Overweight
2017-10-31 開始されました Citigroup Buy
2017-06-30 ダウングレード Goldman Buy → Neutral
2017-04-06 開始されました BofA/Merrill Buy
2017-01-03 アップグレード JP Morgan Neutral → Overweight
2016-02-09 アップグレード Berenberg Hold → Buy
2016-01-04 ダウングレード Morgan Stanley Equal-Weight → Underweight
2015-12-02 ダウングレード HSBC Securities Buy → Hold
2015-11-20 ダウングレード Berenberg Buy → Hold
2015-04-28 ダウングレード Berenberg Buy → Hold
すべてを表示

Grifols Sa Adr (GRFS) 最新ニュース

pulisher
Aug 22, 2025

Grifols (NASDAQ:GRFS) Share Price Crosses Above 200-Day Moving Average – Should You Sell? - Defense World

Aug 22, 2025
pulisher
Aug 07, 2025

Plasma Derived Medicine Market to Reach USD 37.4 Billion by 2034, Growing at 8.05% CAGR - GlobeNewswire Inc.

Aug 07, 2025
pulisher
Jul 29, 2025

CNH Industrial NV (NYSE: CNH) Stock Forecast: Bearish Sentiment Points To -15.21% Downside In 2025 - stocksregister.com

Jul 29, 2025
pulisher
Jun 30, 2025

Oppenheimer Asset Management Inc. Acquires 23,980 Shares of Grifols, S.A. (NASDAQ:GRFS) - Defense World

Jun 30, 2025
pulisher
May 28, 2025

ADMA Biologics Vs. Grifols: Which Plasma Therapy Stock Is The Better Buy? - Barchart.com

May 28, 2025
pulisher
May 22, 2025

Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha

May 22, 2025
pulisher
May 02, 2025

Grifols S.A. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire

May 02, 2025
pulisher
Apr 28, 2025

SMRT’s latest rating updates from top analysts. - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

Investing in Grifols SA ADR (GRFS): What You Must Know - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

Investing in Apellis Pharmaceuticals Inc (APLS) Is Getting More Attractive - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

A company insider recently sold 10,000 shares of News Corp [NWSA]. Should You also Consider to Sale? - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

Raymond James Downgrades Truist Financial Corporation (TFC) to a Mkt perform from an Outperform - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

AT&T, Inc (T) rating upgrades by Exane BNP Paribas - knoxdaily.com

Apr 28, 2025
pulisher
Apr 25, 2025

Grifols SA ADR (GRFS) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com

Apr 25, 2025
pulisher
Apr 25, 2025

Lazard Inc (LAZ) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com

Apr 25, 2025
pulisher
Apr 25, 2025

Can Verra Mobility Corp Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com

Apr 25, 2025
pulisher
Apr 25, 2025

RYAN’s Market Whiplash: 0.32% YTD Rise, -10.03% Plunge in 30 Days - investchronicle.com

Apr 25, 2025
pulisher
Apr 25, 2025

A significant driver of top-line growth: Grifols SA ADR (GRFS) - Sete News

Apr 25, 2025
pulisher
Apr 25, 2025

SpringWorks Therapeutics Inc (SWTX) Stock: From Low to High in 52 Weeks - investchronicle.com

Apr 25, 2025
pulisher
Apr 25, 2025

There is no doubt that Coeur Mining Inc (CDE) ticks all the boxes. - Sete News

Apr 25, 2025
pulisher
Apr 23, 2025

GRFS (Grifols SA ADR) may reap gains as insiders became active recently - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

BHP’s latest rating updates from top analysts. - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

FHN’s latest rating updates from top analysts. - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

Lake Street’s latest rating for ORGO stock - knoxdaily.com

Apr 23, 2025
pulisher
Mar 26, 2025

Fox Corporation [FOX] stock was sold by MURDOCH KEITH RUPERT at the price of US$3.08 million - knoxdaily.com

Mar 26, 2025
pulisher
Mar 20, 2025

6 undervalued stocks with low beta - Morningstar

Mar 20, 2025
pulisher
Mar 10, 2025

Deutsche Bank raises Grifols SA price target to EUR11.00 - Investing.com

Mar 10, 2025
pulisher
Feb 27, 2025

Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha

Feb 27, 2025
pulisher
Nov 29, 2024

Grifols: More Attractive Than In A Very Long Time (NASDAQ:GRFS) - Seeking Alpha

Nov 29, 2024
pulisher
Nov 28, 2024

Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance

Nov 28, 2024
pulisher
Nov 20, 2024

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance

Nov 20, 2024
pulisher
Nov 19, 2024

Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN

Nov 19, 2024
pulisher
Nov 19, 2024

Grifols stock slips as Brookfield offer rebuffed (GRFS:NASDAQ) - Seeking Alpha

Nov 19, 2024
pulisher
Oct 03, 2024

Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha

Oct 03, 2024
pulisher
Aug 22, 2024

Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance

Aug 22, 2024
pulisher
Aug 21, 2024

Grifols shares up on potential takeover by Brookfield - Investing.com

Aug 21, 2024
pulisher
Jul 16, 2024

Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha

Jul 16, 2024
pulisher
Apr 19, 2024

Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire

Apr 19, 2024
pulisher
Mar 07, 2024

Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman - ACCESS Newswire

Mar 07, 2024
pulisher
Feb 17, 2024

AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers

Feb 17, 2024
pulisher
Feb 16, 2024

The 10 Most-Bought and Most-Sold European Stocks - Morningstar

Feb 16, 2024
pulisher
Feb 05, 2024

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance

Feb 05, 2024
pulisher
Jan 26, 2024

ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - PR Newswire

Jan 26, 2024
pulisher
Jan 25, 2024

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Grifols, S.A. - GlobeNewswire

Jan 25, 2024
pulisher
Jan 18, 2024

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Grifols, - GlobeNewswire

Jan 18, 2024
pulisher
Jan 09, 2024

BreakingviewsShort attack intensifies Grifols’ health problem - Reuters

Jan 09, 2024
pulisher
Apr 18, 2023

Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 - PR Newswire

Apr 18, 2023
pulisher
Sep 07, 2022

Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada - PR Newswire Canada

Sep 07, 2022
pulisher
Jul 21, 2022

8 Newly Undervalued 5-Star Stocks - Morningstar

Jul 21, 2022
pulisher
Apr 09, 2021

Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021 - PR Newswire

Apr 09, 2021
pulisher
Nov 11, 2020

Grifols Class B: Buy The Recovery In The U.S. Plasma Business (NASDAQ:GRFS) - Seeking Alpha

Nov 11, 2020

Grifols Sa Adr (GRFS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general SNY
$47.17
price down icon 0.97%
drug_manufacturers_general PFE
$24.58
price up icon 2.27%
$113.01
price down icon 0.91%
$286.46
price up icon 0.31%
drug_manufacturers_general MRK
$81.45
price down icon 0.04%
drug_manufacturers_general NVO
$60.77
price down icon 1.04%
大文字化:     |  ボリューム (24 時間):